School of Medicine Publications and Presentations
Benefit of Endovascular Thrombectomy by Mode of Onset: Secondary Analysis of the DAWN Trial
Document Type
Article
Publication Date
11-2019
Abstract
Background and Purpose—
It is unknown whether the benefit of thrombectomy in late presenting acute stroke patients with imaging evidence of clinical-infarct mismatch is different in patients presenting with wake-up stroke compared with those presenting with witnessed onset or unwitnessed onset.
Methods—
Prespecified secondary analysis was performed from DAWN (Diffusion Weighted Imaging [DWI] or Computerized Tomography Perfusion [CTP] Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention), a multicenter, prospective, randomized clinical trial with blinded end point assessment comparing thrombectomy with the Trevo device against standard medical therapy in patients with acute stroke and clinical-infarct mismatch presenting 6 to 24 hour after the time last seen well. For the purposes of this study, the primary outcome was the proportion of modified Rankin Scale score 0 to 2 at 90 days. Univariable analysis and multivariable logistic regression was used to assess the relationship between outcome and mode of onset.
Results—
All 206 enrolled patients were included in the study. Mode of onset was: wake-up stroke (55.3%, n=114), witnessed onset (12.1%, n=25), and unwitnessed onset (32.5%, n=67) with median time last seen well to randomization (13.4±3.7, 10.0±3.7, 14.1±4.9 hours) respectively. Rates of 90-day modified Rankin Scale score of 0 to 2 and symptomatic intracerebral hemorrhage in the thrombectomy arm were not statistically different across patient onset subtypes (P=0.79 and P=0.40, respectively). The benefit of thrombectomy compared with best medical therapy was maintained across all 3 onset modes (rates of 90-day modified Rankin Scale score of 0 to 2 in patients allocated to thrombectomy versus control: wake-up stroke—49.3% versus 10.6%, witnessed onset—63.6% versus 21.4%, UW—41.4% versus 13.2%; P×interaction=0.79). In univariable and multivariable analyses, mode of onset was not identified as a significant predictor of modified Rankin Scale score 0 to 2 at 90 days.
Conclusions—
In patients with acute ischemic stroke presenting between 6 and 24 hours from time last seen well and harboring clinical-infarct mismatch, the benefit of thrombectomy was similar regardless of the wake-up, unwitnessed, or witnessed mode of onset.
Recommended Citation
Jadhav, A. P., Aghaebrahim, A., Jankowitz, B. T., Haussen, D. C., Budzik, R. F., Bonafe, A., Bhuva, P., Yavagal, D. R., Hanel, R. A., Hassan, A. E., Ribo, M., Cognard, C., Sila, C. A., Zhang, Y., Smith, W. S., Saver, J. L., Liebeskind, D. S., Nogueira, R. G., & Jovin, T. G. (2019). Benefit of Endovascular Thrombectomy by Mode of Onset: Secondary Analysis of the DAWN Trial. Stroke, 50(11), 3141–3146. https://doi.org/10.1161/STROKEAHA.119.025795
Publication Title
Stroke
DOI
10.1161/STROKEAHA.119.025795
Academic Level
faculty
Mentor/PI Department
Neurology
Comments
© 2019 American Heart Association, Inc.